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Alemtuzumab is an anti-CD52 monoclonal antibody that produces rapid depletion of B and T 
lymphocytes and other immune cells expressing the CD52 glycoprotein.1 Lymphocyte counts 
fall rapidly after treatment and steadily increase over the next 6-12 months.1 In phase III trials 
of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), serious infections were 
surprisingly uncommon given the profound and sustained period of lymphopenia.2, 3 
Opportunistic infections including oesophageal candidiasis3, reactivation of latent 
tuberculosis2, 3, listeria meningitis4 and cerebral nocardiasis5 have been reported, though 
rarely.  
 
In this issue of Multiple Sclerosis Journal further cases are reported of early opportunistic 
infections in RRMS patients receiving alemtuzumab. Clerico and colleagues describe two 
patients who developed cytomegalovirus (CMV) syndrome within the first month after 
alemtuzumab, with fever and evidence of CMV-DNA in blood samples. The patients improved 
after treatment with ganciclovir and valganciclovir. Sheikh-Taha and Cormon describe a 
patient with RRMS who developed pulmonary nocardiasis five weeks after receiving 
alemtuzumab. The patient improved on treatment with meropenem. A case of fulminant 
cerebral nocardiasis was also recently reported in an RRMS patient treated with 
alemtuzumab.5 
 
Neurologists treating patients with alemtuzumab need to be vigilant to possible opportunistic 
infections, particularly in the first few months after treatment. Based on experience in phase 
III trials these appear to be rare2, 3, but as alemtuzumab is used increasingly in routine clinical 
practice, including in patients with medical co-morbidities, greater exposure to previous 
disease-modifying treatments, and more disability, the incidence of serious infections may 
rise. Moreover infections like CMV and nocardiasis need to be actively considered, since 
outside the setting of immunosuppression they are not common. Phase IV post-authorisation 
studies are underway that will be helpful in clarifying the frequency of these potentially serious 
adverse events in the real-world setting. Neurologists treating MS with potent agents need to 
expect the unexpected. 
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